13.2 Labeling of Dispensed Drugs

Why the vial is an MPJE document

Quick Answer: CGS § 20-617(a) puts quantity and a prominent expiration date (no later than the manufacturer’s, based on labeled storage) on every prescription container. § 20-617(b) adds manufacturer plus MedWatch web address and toll-free number for a drug sold only by generic name. § 20-617(c) adds, on a generic-for-brand substitution, the generic name and the brand name substituted for. Federal 21 U.S.C. § 353(b)(2) still requires pharmacy name and address, Rx (serial) number, date, prescriber, patient, and directions. Auxiliary labels do not replace counseling (CGS § 20-614(d)).

NABP Competency 3.5 is the label the patient actually takes home. A correctly selected tablet in a vial that omits the expiration date, the substituted brand, or the MedWatch line is still a misbranding / Chapter 400j problem. Chapter 6 taught adulteration versus misbranding; this section is what Connecticut and DEA require on the container.

RCSA § 20-576-25 is the short Connecticut regulation: all prescriptions dispensed in pharmacies, and all outpatient prescriptions dispensed in institutional pharmacies, shall be labeled, and those labels shall contain all information required by federal and state statutes and regulations. There is no separate RCSA laundry list that replaces § 20-617. The regulation is a pointer: stack the federal floor, then the Connecticut extras.

Federal floor — 21 U.S.C. § 353(b)(2) and DEA CS labels

Durham-Humphrey, 21 U.S.C. § 353(b)(2), exempts a drug dispensed by filling or refilling a prescription from most of the manufacturer’s § 352 labeling if the dispensed container bears:

• The name and address of the dispenser (the pharmacy);
• The serial number and date of the prescription or of its filling;
• The name of the prescriber;
• The name of the patient, if stated in the prescription; and
• The directions for use and cautionary statements, if any, contained in the prescription.

Missing those elements is how a correctly filled vial becomes misbranded at the point of dispensing. Connecticut does not waive this floor. RCSA § 20-576-25 pulls it in.

Controlled-substance overlays:

• 21 CFR 1306.14(a) (Schedule II): date of filling, pharmacy name and address, serial number, patient, prescribing practitioner, directions and cautionary statements required by the prescription or by law.
• 21 CFR 1306.24(a) (Schedule III–V): pharmacy name and address, serial number and date of initial filling, patient, practitioner, directions and cautionary statements.
• 21 CFR 290.5: any CII, III, or IV dispensed to or for a patient must bear “Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.” Schedule V is not in that sentence.
• Institutional administration to an ultimate user can drop the outpatient CS label if the quantity and control conditions in 1306.14(c) (CII: not more than a 7-day supply at one time) or 1306.24(c) (CIII–V: not more than a 34-day supply or 100 dosage units, whichever is less) are met. That is a hospital / LTCF administration exception, not a community snap-cap shortcut.

Central-fill CS labels add the retail pharmacy name and address plus a unique identifier (the central fill DEA number) under 1306.14(b) / 1306.24(b). Connecticut’s own central-dispense label (name, address, and telephone of both pharmacies plus § 20-617 data) lives in RCSA § 20-576-77(b) and is the Chapter 17 operational tease — do not skip § 20-617 because a robot in another building printed the vial.

CGS § 20-617 — quantity, expiration, generic, manufacturer, MedWatch

Subsection (a) applies to each prescription container:

1. The quantity of prescribed drug placed in the container, in addition to any other information required by law; and
2. A prominently printed expiration date based on the manufacturer’s recommended conditions of use and storage that an ordinary individual can read and understand. That date shall be no later than the expiration date determined by the manufacturer.

Two traps sit in (a)(2). A pharmacist beyond-use date that is later than the manufacturer’s expiration is unlawful. A tiny “EXP” string that a patient cannot read is not “prominently printed.” Storage matters: the date assumes the manufacturer’s labeled conditions; a reconstituted antibiotic that must be refrigerated is not given a room-temperature manufacturer date that outruns the reconstitution BUD.

Subsection (b) (P.A. 15-219, effective January 1, 2016) is the generic-name-only extra. In addition to (a) and (c), for a drug sold only by generic name and not by brand name, the pharmacist shall include on the label or on the receipt or other similar packaging:

1. The name of the manufacturer of the generic drug in the container; and
2. The Internet web site address and toll-free telephone number for FDA’s safety information and adverse event reporting program (MedWatch).

MedWatch is not optional fine print on a website footer. It may live on the vial or on the receipt/bag documentation. Omitting both is a § 20-617(b) miss. Brand-only fills are outside (b); the MedWatch line is aimed at the patient who received “lisinopril” with no brand name on the bottle.

Subsection (c) is the substitution extra. If the pharmacist substitutes a generic-name drug for a brand-name drug, the container shall show:

1. The name of the generic drug placed in the container; and
2. The brand name of the drug that the generic drug was substituted for.

CGS § 20-619 is the substitution process (Orange Book, DAW, patient notice) — Chapter 14. Its labeling slice still matters here: a prescription dispensed by a pharmacist shall bear upon the label the name of the drug or biological product in the container unless the prescriber instructs otherwise, and a substituted product is labeled with the dispensed name (and manufacturer if there is no brand name). § 20-617(c) is the more specific “generic and the brand you replaced” sentence the exam quotes. Do not label a substituted vial with only the brand the patient asked for at the window.

Connecticut’s stacked outpatient label — table and list

A working list of what is not a substitute for those elements:

• A Medication Guide or Patient Package Insert in the bag does not replace the container label.
• An NDC on the manufacturer stock bottle is not the outpatient Rx label.
• A drowsiness, shake well, or take with food auxiliary sticker is a cautionary extra. It does not satisfy CGS § 20-614(d)’s offer for the pharmacist to discuss the drug and counsel the patient. Chapter 11 is the counseling leaf; this leaf only needs the negative: auxiliary labels are not counseling.
• A technician-applied flag that says “generic for Lipitor” is useful only if § 20-617(c)’s two names actually appear as required. A handwritten brand nickname is not the statute.

Realistic Connecticut scenarios

A New Britain pharmacist fills #30 lisinopril 10 mg (generic only, no brand on the order) with a label that has pharmacy name and address, Rx number, today’s date, the cardiologist, the patient, “take one tablet daily,” and quantity 30 — but no expiration date and no MedWatch line on the vial or the receipt. § 20-617(a)(2) and (b) both fail. Adding a “may cause dizziness” sticker does not repair either miss and does not replace the counseling offer.

A Hamden patient presents Lipitor 20 mg. The pharmacist substitutes atorvastatin (lawful substitution is Chapter 14). § 20-617(c) requires the generic name and the brand name substituted for on that container. Labeling the vial “Lipitor” only, because “that’s what she asked for,” is the substitution-label miss. § 20-617(b)’s manufacturer/MedWatch extras still attach if the product is sold by generic name.

A Bridgeport CII oxycodone vial that omits “Caution: Federal law prohibits the transfer…” is a 21 CFR 290.5 miss even if every § 20-617 box is ticked. A hospital unit-dose CII sent for inpatient administration, not more than a 7-day supply, never in the patient’s possession before administration, with institutional controls, is the 1306.14(c) fact pattern — not a community exemption.

Official anchors

• CGS § 20-617 — quantity, expiration, generic manufacturer, MedWatch, substitution names.
• CGS § 20-619 — dispensed-product name on the label; substitution process in Chapter 14.
• 21 U.S.C. § 353(b)(2) — dispenser name/address, serial number, date, prescriber, patient, directions.
• 21 CFR 1306.14 / 1306.24 / 290.5 — CS labels and transfer caution.
• RCSA § 20-576-25 — labels must contain all federally and state-required information.